相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
Gissette Reyes-Soffer et al.
CIRCULATION (2017)
Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism
Gerald F. Watts et al.
CIRCULATION (2017)
Pharmacological management of diabetic dyslipidemia
T. D. Filippatos et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)
Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin-naive patients with coronary artery disease
Die Hu et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Hypertriglyceridaemia and risk of coronary artery disease
Zeljko Reiner
NATURE REVIEWS CARDIOLOGY (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia Results Up to 4 Years From the Open-Label OSLER-1 Extension Study
Michael J. Koren et al.
JAMA CARDIOLOGY (2017)
Pathophysiology of Diabetic Dyslipidaemia
Theodosios Filippatos et al.
CURRENT VASCULAR PHARMACOLOGY (2017)
Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program)
Daniel Gaudet et al.
AMERICAN JOURNAL OF CARDIOLOGY (2017)
Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms
Amirhossein Sahebkar et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases
Josefa Girona et al.
CARDIOVASCULAR DIABETOLOGY (2016)
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
Robert S. Rosenson et al.
CARDIOVASCULAR DRUGS AND THERAPY (2016)
Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms
Hagai Tavori et al.
CARDIOVASCULAR RESEARCH (2016)
Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering
Giuseppe Danilo Norata et al.
CARDIOVASCULAR RESEARCH (2016)
Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
Vera Bittner
CIRCULATION (2016)
Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations
Hayato Tada et al.
CIRCULATION JOURNAL (2016)
PCSK9 and Lipoprotein(a) The Plot Thickens
Peter P. Toth
CIRCULATION RESEARCH (2016)
Sortilin: A novel regulator in lipid metabolism and atherogenesis
Li-yuan Zhong et al.
CLINICA CHIMICA ACTA (2016)
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials
Michel Farnier et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Effects of Statin Therapy on Plasma Proprotein Convertase Subtilisin/kexin Type 9 and Sortilin Levels in Statin-Naive Patients with Coronary Artery Disease
Tsuyoshi Nozue et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2016)
Evaluating The Roles Of PCSK9 And Specific Receptors In Lipoprotein(A) Catabolism
Marlys Koschinsky et al.
Journal of Clinical Lipidology (2016)
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role
Frederick J. Raal et al.
JOURNAL OF LIPID RESEARCH (2016)
Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo
Peter P. Toth et al.
LIPIDS IN HEALTH AND DISEASE (2016)
Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease
Tsuyoshi Nozue et al.
LIPIDS IN HEALTH AND DISEASE (2016)
Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence
Nicola Ferri et al.
TRANSLATIONAL RESEARCH (2016)
Analysis of the association between plasma PCSK9 and Lp(a) in Han Chinese
S-H. Yang et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2016)
Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population
Pia R. Kamstrup et al.
JACC-HEART FAILURE (2016)
Cholesteryl ester transfer protein inhibitors: challenges and perspectives
T. D. Filippatos et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2016)
PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver
Annie Demers et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity Multicenter Tracer Kinetic Study
Jan Boren et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
Xin-Lin Zhang et al.
BMC MEDICINE (2015)
Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state
Dick C. Chan et al.
CLINICAL SCIENCE (2015)
Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor
Rocco Romagnuolo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients
Ymene Nekaies et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2015)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta-Analysis of 20 Randomized Controlled Trials
Chuanwei Li et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2015)
Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study
Danish Saleheen et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
PCSK9 levels in abdominally obese men: Association with cardiometabolic risk profile and effects of a one-year lifestyle modification program
Benoit J. Arsenault et al.
ATHEROSCLEROSIS (2014)
Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels
H. Abujrad et al.
ATHEROSCLEROSIS (2014)
The Hypercholesterolemia-Risk Gene SORT1 Facilitates PCSK9 Secretion
Camilla Gustafsen et al.
CELL METABOLISM (2014)
Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor-Dependent and -Independent Mechanisms
Shirya Rashid et al.
CIRCULATION (2014)
PCSK9: A Key Modulator of Cardiovascular Health
Nabil G. Seidah et al.
CIRCULATION RESEARCH (2014)
Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins
Arjan J. Kwakernaak et al.
CLINICAL BIOCHEMISTRY (2014)
Circulating PCSK9 is a strong determinant of plasma triacylglycerols and total cholesterol in homozygous carriers of apolipoprotein ε2
Martijn C. G. J. Brouwers et al.
CLINICAL SCIENCE (2014)
Latest developments in the treatment of lipoprotein (a)
Sven Bos et al.
CURRENT OPINION IN LIPIDOLOGY (2014)
Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease
Rui-Xia Xu et al.
LIPIDS IN HEALTH AND DISEASE (2014)
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Dirk J. Blom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events
Anand Rohatgi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study
Theodosios D. Filippatos et al.
ARCHIVES OF MEDICAL SCIENCE (2013)
Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: Relationship with lipoprotein response to antiproteinuric treatment
Arjan J. Kwakernaak et al.
ATHEROSCLEROSIS (2013)
Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia
Evan A. Stein et al.
CIRCULATION (2013)
High-Sensitivity C-Reactive Protein and Cardiovascular Disease A Resolute Belief or an Elusive Link?
Omair Yousuf et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Small High-Density Lipoprotein (HDL) Subclasses are Increased with Decreased Activity of HDL-Associated Phospholipase A2 in Subjects with Prediabetes
Theodosios D. Filippatos et al.
LIPIDS (2013)
Decreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9
Seungbum Choi et al.
LIPIDS IN HEALTH AND DISEASE (2013)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)
Maryssa Canuel et al.
PLOS ONE (2013)
Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study
T. D. Filippatos et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2013)
PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
Rose Q. Do et al.
CURRENT CARDIOLOGY REPORTS (2013)
Proprotein convertases in high-density lipoprotein metabolism
Seungbum Choi et al.
BIOMARKER RESEARCH (2013)
High density lipoprotein and cardiovascular diseases
Theodosios D. Filippatos et al.
WORLD JOURNAL OF CARDIOLOGY (2013)
A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination
Theodosios D. Filippatos
CARDIOVASCULAR DRUGS AND THERAPY (2012)
A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease
Anastazia A. Kei et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2012)
Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue
Anna Roubtsova et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia
Aris P. Agouridis et al.
EXPERT OPINION ON PHARMACOTHERAPY (2011)
High Doses of Rosuvastatin are Superior to Low Doses of Rosuvastatin Plus Fenofibrate or n-3 Fatty Acids in Mixed Dyslipidemia
A. P. Agouridis et al.
LIPIDS (2011)
Leptospirosis is Associated with Markedly Increased Triglycerides and Small Dense Low-Density Lipoprotein and Decreased High-Density Lipoprotein
Irene F. Gazi et al.
LIPIDS (2011)
The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations
Lynn Htet Htet Aung et al.
LIPIDS IN HEALTH AND DISEASE (2011)
Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis
Amit V. Khera et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Plasma triglyceride levels and body mass index values are the most important determinants of preβ-1 HDL concentrations in patients with various types of primary dyslipidemia
Vasilis Tsimihodimos et al.
ATHEROSCLEROSIS (2010)
Combination of Fenofibrate with Non-Statin Drug Regimens
A. P. Agouridis et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Effects of Plant Sterols and Stanols Beyond Low-Density Lipoprotein Cholesterol Lowering
Christos S. Derdemezis et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2010)
Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome
Renata Belfort et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia
Cedric Le May et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Effects of hormonal treatment on lipids in patients with cancer
T. D. Filippatos et al.
CANCER TREATMENT REVIEWS (2009)
Plasma PCSK9 Is Associated with Age, Sex, and Multiple Metabolic Markers in a Population-Based Sample of Children and Adolescents
Alexis Baass et al.
CLINICAL CHEMISTRY (2009)
Effects of orlistat, alone or combined with hypolipidemic drugs, on cardiovascular risk factors
T. D. Filippatos et al.
CLINICAL LIPIDOLOGY (2009)
Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Dose-dependent Effect of Rosuvastatin Treatment on HDL-subfraction Phenotype in Patients With Primary Hyperlipidemia
Michael S. Kostapanos et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2009)
Genetic and Metabolic Determinants of Plasma PCSK9 Levels
Susan G. Lakoski et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Chylomicron remnants are increased in the postprandial state in CD36 deficiency
Daisaku Masuda et al.
JOURNAL OF LIPID RESEARCH (2009)
Alterations in the High Density Lipoprotein Phenotype and HDL-Associated Enzymes in Subjects with Metabolic Syndrome
K. G. Lagos et al.
LIPIDS (2009)
The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome
T. D. Filippatos et al.
DIABETES OBESITY & METABOLISM (2008)
Treatment of hyperlipidaemia with fenofibrate and related fibrates
Theodosios Filippatos et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia
E. S. Nakou et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) activity in healthy obese women
T. Tzotzas et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2008)
A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia
Michael S. Kostapanos et al.
CLINICAL THERAPEUTICS (2007)
Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia
Mihalis Kalogirou et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Molecular biology of PCSK9: its role in LDL metabolism
Jay D. Horton et al.
TRENDS IN BIOCHEMICAL SCIENCES (2007)
Serum lipoprotein(a) levels and apolipoprotein(a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals
Haralampos J. Milionis et al.
ATHEROSCLEROSIS (2006)
Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene - Long-term follow-up and treatment response
RP Naoumova et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study
TD Filippatos et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial
A Keech et al.
LANCET (2005)
The effects of orlistat on metabolic parameters and other cardiovascular risk factors
DN Kiortsis et al.
DIABETES & METABOLISM (2005)
Endoplasmic reticulum localization of the low density lipoprotein receptor mediates presecretory degradation of apolipoprotein B
DL Gillian-Daniel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
分享论文
